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Aim: Potent risk factors at both genetic and non-genetic levels are accountable for suscep-
tibility and instigation of different cardiovascular phenotypes. Recently, homocysteine is
being identiﬁed as an important predictor for cardiovascular diseases. Homocysteine
remethylation plays a key role in the synthesis of methionine and S-adenosine methionine.
Methylenetetrahydrofolate reductase (MTHFR) and methionine synthase (MTR) genes are
known to regulate the homocysteine remethylation reaction and higher homocysteine level
is signiﬁcantly associated with diverse cardiovascular phenotypes. In this context, we aimed
to carry out a study on the association of MTHFR (C677T) and MTR (A2756G) gene polymor-
phism with CVD in population of Jammu region of J&K state.
Materials and methods: A total of 435 individuals were enrolled (195 CVD patients and 240
controls) for the case–control study. Genotyping of MTHFR C677T and MTR A2756G gene
polymorphism was done by PCR-RFLP technique. Biochemical parameters were estimated
by biochemical analyser.
Results: Metabolic variables such as serum LDL-C, TC and TG were signiﬁcantly higher in
patients ( p < 0.0001), whereas serum HDL-C was higher in controls. Majority of the
patients were having history of hypertension (57.44%; p < 0.0001) as a concomitant
condition. The evaluation of genetic association showed that, MTHFR C6877T (OR:
8.89, 95% CI: 2.01–39.40) and MTR A2756G (OR: 1.48, 95% CI: 1.09–2.00) polymorphisms
associated  with higher risk of CVD.
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Conclusion: The present study reveals signiﬁcant differences in nongenetic variables among
patients and control as well as association of gene polymorphisms with CVD risk.
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Notwithstanding the immense advancement and sophisti-
cation in healthcare system, the challenge to check the
incidence of cardiovascular diseases (CVDs) still remains,
be it a developed nation like the USA or a developing country
like India. It is a matter of great concern that CVDs alone
would soon be the single largest cause of mortality account-
ing for more than a third of all deaths worldwide.1 Besides
well established risk factors such as hypertension (HTN),
diabetes mellitus (DM), obesity, smoking, male gender,
dyslipidemia, sedentary lifestyle and family history,2–5
genetic alterations in the genes controlling homocysteine
and folate metabolism are also linked to onset of CVDs.6,7
Several investigators have implicated elevated plasma
homocysteine as an independent marker for atherosclerotic
cardiovascular condition.8–11 Homocysteine and folate me-
tabolism is dependent on couple of genes performing their
speciﬁc role, but two genes namely MTR and MTHFR genes
are considered critical genes for development of diseased
cardiovascular phenotypes particularly congenital heart
diseases12,13 and coronary artery diseases.14–16 MTHFR
enzyme is a co-factor for conversion of 5,10-methylenete-
trahydrolate to 5-methyltetrahydrofolate. It has been dem-
onstrated that C677T polymorphism in exon 4 of MTHFR
gene reduces enzyme activity, which may be a plausible
reason for elevated concentration of plasma homocyste-
ine.17–21 MTR is engaged in dual performance of both
demethylation of 5-methyltetrahydrofolate to tetrahydrofo-
late and also, remethylation of homocysteine to methionine
by utilizing methyl group donated by 5-methyltetrahydrofo-
late. A common polymorphism in the MTR gene (A2756G)
is associated with hyperhomocystenemia and DNA hypo-
methylation.22–24 The distribution of MTHFR and MTR gene
SNPs project a higher degree of heterogeneity not among
worldwide populations25–28 but a transient difference was
observed in allelic distribution among different Indian
populations due to diverse ethnicity.29,30 The state of
Jammu & Kashmir represents diverse cultural and genetic
heritage belonging to Kashmiri (Kashmir), Dogra (Jammu)
and Ladakhi populations (Ladakh). The ethnicity, genetic
makeup, basic lifestyle and dietic pattern of an individual
can greatly inﬂuence the onset and pathogenesis of disease.
The lack of any molecular level study in context to CVD,
targeting the populations of Jammu, called for undertaking
the research work documented herein. We have attempted
to assess link of MTHFR (C677T) and MTR (A2756G) gene
variation and risk of CVD in populace of Jammu region of
J&K state.2. Materials and methods
2.1. Study population
The study population comprised of 195 CVD cases (men = 128;
women = 67) and 240 healthy controls (men = 145; wom-
en = 95), who were genetically unrelated and belonging to
Jammu region of Jammu & Kashmir state. Eligible cases were
patients with major CVD phenotypes encompassing coronary
artery disease, acquired arrhythmia (associated with athero-
sclerotic coronary condition) and myocardial infarction (in-
cluding acute coronary syndrome).
2.2. Ethical approval
The present study design was duly approved by Animal and
Human Experimentation Ethical Committee (AHEEC), Univer-
sity of Jammu, Jammu and Kashmir, India. Each study
participant was made aware of the nature and scope of the
study. Data and blood collection from study individuals was
effected after having their informed written consent.
2.3. Data collection and clinical evaluation
Non-genetic data including age, dwelling, age of onset and
duration of disease, history of HTN/DM, habit of smoking/
alcohol intake, sedentary lifestyle, family history, diet pattern,
anthropometric (body mass index and waist hip ratio) and
physiometric variables (SBP, DBP, PR and PP) were recorded in
pre-designed health datasheet from each study participant.
2.3.1. Demographic proﬁle
The dwelling pattern of the study participants was divided into
urban (who had the advantage of instant access to urbane
facilities), sub-urban (who dwelled at a distance) and rural
(who had remote access to urbane settlements) areas.
2.3.2. Behavioral determinants
Smokers were categorized as current smoker (who smokes one
or more cigarette/tobacco per day), ex-smoker (person with
former smoking habit for at least 1 year) and non-smoker
(person who never smoked). Alcohol intake was assessed in
three categories as: current alcoholics (person who drinks per
day or week), former alcoholics (subjects with previous history
of alcohol intake) and non-alcoholics (person who never
drunk). Physical activity was assessed as performers (person
involved in any signiﬁcant bodily activity like walking/jogging/
exercise as a minimum of 30 min) and sedentary (person not
involved in any bodily exercise).
Fig. 1 – Showing the restriction digestion of MTR PCR
product with HaeII enzyme. Lane no. 1 – marker, Lanes 2, 3,
6 and 7 – homozygous wild, Lanes 4 and 5 – heterozygous.
Fig. 2 – Showing the restriction digestion of MTHFR PCR
product with HinfI enzyme. Lane no. 9 – marker, Lanes 1, 2,
3, 5, 6 and 8 – homozygous wild, Lanes 4 and 7 –
heterozygous.
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Body mass index (BMI) was calculated as ratio of weight and
height (weight in kg/height in m2) and the values were deﬁned
according to the recommendations proposed by WHO for
Asians.31 Waist hip ratio (WHR) was obtained as waist
circumference divided by hip circumference and was deﬁned
as ≥0.90 for men and ≥0.80 for women.32
2.3.4. Physiometric characteristics
According to JNC7 guidelines patient on antihypertensive
medications or having a systolic blood pressure (SBP) of
140 mmHg or greater and a diastolic blood pressure (DBP) of
90 mmHg or greater were considered as having HTN.33 Pulse
rate (PR) was counted by feeling radial artery at the wrist over
one minute. Pulse pressure (PP) was calculated by applying
formula: PP = Systolic blood pressure (SBP)  Diastolic blood
pressure (DBP).
2.4. Biochemical proﬁling
Five milliliters of peripheral blood was collected in EDTA
vacutainers from each fasting study individual. Lipid proﬁling
(LDL-C, HDL-C, TC and TG) was done on automated biochemi-
cal analyzer (Roche, Cobas CIII).
2.5. DNA isolation and genotyping
Genomic DNA was isolated from peripheral blood lymphocytes
using phenol–chloroform–isoamyl extraction.34 Qualiﬁcation
and quantiﬁcation of extracted DNA were done by using agarose
gel electrophoresis and spectrophotometry. The MTHFR C677T
(rs1801133) and MTR A2756G (rs1805087) gene polymorphisms
were determined by polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) genotyping tech-
nique. The MTHFR C677T polymorphism was detected by target
DNA ampliﬁcation using the forward primer 50-TGA AGG AGA
AGG TGT CTG CGG GA-30 and the reverse primer 50-AGG ACG GTG
CGG TGA GAG TG-30 described by Matsuo et al. (2001).23 For
detection of genotypes of MTR A2756G variants following site
speciﬁc oligonucleotide primers were used: forward primer
50-TGT TCC AGA CAG TTA GAT GAA AAT C-30 and the reverse
primer 50-GAT CCA AAG CCT TTT ACA CTC CTC-30.23
2.5.1. PCR conditions
Standard PCR reactions for both MTHFR and MTR genes were
performed in Applied Biosystems thermal cycler (Make Veriti
by Life Technology, Singapore) using 25 ml of ﬁnal reaction
mixture containing 2 ml DNA (50 ng–100 of genomic DNA), 5 ml
ﬂexi buffer (5), 0.5 ml dNTPs (10 mM), 0.3 ml Taq polymerase
(5 U/ml), 0.5 ml each primers (100 pmol/ml) and 13.7 ml sterile
distilled water to make up the ﬁnal volume. PCR thermal
cycling conditions for MTHFR 677 were: pre-denaturation –
2 min at 94 8C, denaturation – 30 s at 94 8C, annealing – 1 min at
62 8C, extension – 30 s at 72 8C and ﬁnal extension – 7 min at
72 8C. The PCR was carried out for 40 cycles. For MTR gene, the
conditions were as follows: pre-denaturation – 4 min at 95 8C,
followed by 35 cycles with denaturation – 1 min at 95 8C,
annealing – 1.5 min at 61 8C, extension – 1 min at 72 8C and
ﬁnal extension – 7 min at 72 8C. The ampliﬁed PCR products
were 198 bp for MTHFR gene and 211 bp for MTR gene.2.5.2. RFLP conditions
The restriction digestion was performed by using 0.3 ml of
restriction enzyme (10 U/ml), 2 ml NEB restriction buffer 4, 10 ml
of ampliﬁed PCR product and 7.7 ml of sterile distilled water to
reach total volume of 20 ml. The restriction endonuclease used
for detection of MTHFR C677T polymorphism was Hinf I (New
England Biolabs) and for MTR, it was Hae III (New England
Biolabs). The restriction digestion mixture was given overnight
incubation at 37 8C.
2.5.3. Detection of genotypes
The products of restriction digestion were separated on a 4%
agarose gel pre-stained with ethidium bromide and analyzed
under UV light. Genotypes of all individuals were noted as:
MTHFR C677T polymorphism: CC (wild) = 198 bp; CT (het-
ero) = 198 bp + 175 bp + 23 bp; and TT (mutant) = 175 bp
+ 23 bp (Fig. 1). MTR A2756G polymorphism: AA (wild)
= 211 bp; AG (hetero) = 211 bp + 131 bp + 80 bp; and GG (mu-
tant) = 131 bp + 80 bp (Fig. 2).
2.6. Statistical analysis
For non-genetic variables, mean and standard deviation
were calculated and Student's t-test was performed to
calculate the difference between the patients and controls.
The allele frequencies were calculated by allele counting for
each genetic marker. Hardy–Weinberg equation and the
differences in genotypic frequencies were examined by
using Chi-square test. The odd-ratios (OR) for different
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 4 2 1 – 4 3 0424MTHFR and MTR genotypes/alleles were calculated with 95%
conﬁdence interval (CI) by unconditional logistic regression
and concurrently, p values were calculated to conclude risk
association with CVD. A value of p < 0.05 was considered as
statistically signiﬁcant. Statistical analysis was performed by
using Statistical Package for Social Sciences (SPSS) software
version 17.
3. Results
3.1. Non-genetic factors
Different non-genetic variables including physiometric, an-
thropometric and biochemical variables along with personal
history of study participants are enlisted in Tables 1 and 2.
3.1.1. Demographic characteristics
During the study course, we enrolled a good deal of male
patients (n = 128) as compared to females (n = 67). Majority of
the patients were natives of urban (43.59) and sub-urban
(36.92%) areas of Jammu region. The dwelling pattern of
controls showed that most of them belong to sub-urbanTable 1 – Prevalence of CVD risk factors in study groups.
Parameters Patients 
Men
(n = 128)
Women
(n = 67)
Total
(n = 195)
M
(n 
Age (years) 58.98  15.08 53.40  13.94 57.06  14.90 42.03
Dwelling
Urban 61 (47.66%) 24 (35.82%) 85 (43.59%) 28 (1
Sub-urban 49 (38.28%) 23 (34.33%) 72 (36.92%) 65 (4
Rural 18 (14.06%) 20 (29.85%) 38 (19.49%) 52 (3
Physical activity
Performers 67 (52.34%) 23 (34.33%) 90 (46.15%) 102 (
Sedentary 61 (47.66%) 44 (65.67%) 105 (53.85%) 43 (2
Smoking
Current 25 (19.53%) 1 (1.5%) 26 (13.33%) 34 (2
Formers 38 (29.69%) 1 (1.5%) 39 (20%) 8 (5.
Non-smokers 65 (50.78%) 65 (97.0%) 130 (66.67%) 103 (
Duration of smoking
(years)
24.51  13.63 13.5  9.19 24.17  13.60 11.90
Alcohol intake
Current 43 (33.59%) – 43 (22.05%) 27 (1
Former 16 (12.5%) – 16 (8.21%) – 
Never 69 (53.91%) 67 (100%) 136 (69.74%) 118 (
Duration of alcohol
intake (years)
22.12  14.55 – 21.14  13.75 9.07 
Diet pattern
Vegetarian 25 (19.53%) 33 (49.25%) 58 (29.74%) 52 (3
Non-vegetarian 103 (80.47%) 34 (50.75%) 137 (70.26%) 93 (6
History of HTN
Yes 81 (63.28%) 31 (46.27%) 112 (57.44%) – 
No 47 (36.72%) 36 (53.73%) 83 (42.56%) – 
History of DM
Yes 25 (19.53%) 13 (19.40%) 38 (19.49%) – 
No 103 (80.47%) 54 (80.60%) 157 (80.51%) – 
HTN, hypertension; DM, diabetes mellitus.
* Signiﬁcant values.(44.17%) areas of Jammu region followed by rural (33.75%) and
urban (22.08%) vicinity.
3.1.2. Behavioral determinants and diet pattern
The CVD patients were elder than the controls, with a mean
age of 57.06  14.90 years compared to 41.91  12.53 years in
the control group. Sedentary behavior was signiﬁcantly
exhibited by patient group (53.85%; p < 0.0001) as compared
to controls (32.5%). The prevalence of physical inactivity was
higher in female patients in contrast to male patients in the
present study (67.12% vs 48.18%). Smoking appeared to be
potent risk factor for CVD in our population with 13.33%
patients engaged in current smoking habit [OR = 1.12, 95% CI
(0.6531–1.9238); p = 0.6787], 21.90% were former smokers
[OR = 7.35, 95% CI (3.33–16.23); p < 0.001] and 66.67% were
non-smokers. On the contrary, frequency of non-smokers was
higher among controls. The pattern of alcohol intake was
higher in cases (22.05% current alcoholics and 8.21% former
alcoholics) than controls (11.25% current alcoholics). Women
participants of our study were not reported to be engrossed in
drinking habit owing to cultural perspective. Moreover, female
subjects of the present study were not found to be actively
engaged in smoking as like male subjects. 70.26% of patientsControls OR p-Value 95% CI
en
= 145)
Women
(n = 95)
Total
(n = 240)
  12.58 41.73  12.51 41.91  12.53 – – –
9.31%) 25 (26.31%) 53 (22.08%) – – –
4.83%) 41 (43.16%) 106 (44.17%) – –
5.86%) 29 (30.53%) 81 (33.75%) –
70.34%) 60 (63.16%) 162 (67.5%) Ref
9.66%) 35 (36.84%) 78 (32.5%) 2.42 <0.0001* 1.64–3.58
3.45%) 2 (2.11%) 36 (15%) 1.09 0.76 0.63–1.89
52%) – 8 (3.33%) 7.35 <0.001* 3.33–16.23
71.03%) 93 (97.89%) 196 (81.67%) Ref
  13.82 30.5  34.65 12.75  15.01 – – –
8.62%) – 27 (11.25%) 2.49 0.0007* 1.47–4.22
– – – – –
81.38%) 95 (100%) 213 (88.75%) Ref.
 5.05 – 9.07  5.05 – – –
5.86%) 55 (57.89%) 107 (44.58%) Ref
4.14%) 40 (42.11%) 133 (55.42%) 1.90 0.002* 1.27–2.83
– – – <0.0001* –
– – –
– – – 0.0001* –
– –
Table 2 – Physiometric, anthropometric and biochemical variables in the study groups.
Parameters Patients Controls p-Value
Men
(n = 128)
Women
(n = 67)
Total
(n = 195)
Men
(n = 145)
Women
(n = 95)
Total
(n = 240)
Blood pressure (mmHg)
Systolic (SBP) 143.75  19.53 138.19  23.66 141.84  21.15 125.45  7.31 122.73  7.94 124.37  7.67 <0.0001*
Diastolic (DBP) 88.63  9.46 87.04  10.58 88.09  9.86 86.04  10.16 83.82  8.74 85.16  9.67 0.002*
Pulse pressure (PP) 55.19  15.72 51.15  18.03 53.80  16.62 39.41  8.93 38.90  6.73 39.21  8.12 <0.0001*
Pulse rate (PR) 80.53  11.38 85.12  17.34 82.11  13.85 73.43  4.16 72.94  2.76 73.24  3.67 <0.0001*
BMI 24.11  4.30 24.67  5.65 24.30  4.80 23.01  3.80 22.46  4.50 22.79  4.07 0.0004*
WHR 1.00  0.07 0.99  0.10 1.00  0.08 0.95  0.05 0.95  0.05 0.95  0.05 <0.0001*
Total cholesterol
(TC) (mg/dl)
184.26  58.85 185.30  65.23 184.62  60.95 131.44  31.17 124.82  31.67 128.82  31.47 <0.0001*
Triglycerides
(TG) (mg/dl)
207.95  86.16 198.13  71.69 204.58  81.42 124.13  26.75 122.04  26.45 123.30  26.6 <0.0001*
HDL-C (mg/dl) 35.62  9.95 37.24  9.54 36.18  9.82 50.81  7.03 52.28  6.25 51.39  6.75 <0.0001*
LDL-C (mg/dl) 126.66  69.75 135.76  74.53 129.78  71.37 78.26  18.56 75.58  20.37 77.20  19.30 <0.0001*
Values are mean  SD.
SBP, systolic blood pressure; DBP, diastolic blood pressure, BMI, body mass index; WHR, waist hip ratio, HDL, high density lipoprotein
cholesterol; LDL-C, low density lipoprotein cholesterol.
* Signiﬁcant values.
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were also found to be keen for non-vegetarian diet. Vegetarian
diet was more prevalent in female participants.
3.1.3. Anthropometric, physiometric, metabolic characteristics
and co-morbid disease
BMI and WHR were calculated for both study groups as
increment in these anthropometric variables adds to risk
of CVD in an individual. It was seen that patients had
signiﬁcantly higher BMI and WHR values (24.30  4.80 and
1.00  0.08) than controls (22.79  4.07 and 0.95  0.05) respec-
tively. The SBP, DBP, PP, and PR were signiﬁcantly higher in
CVD patients as compared with controls. Signiﬁcant distinc-
tion was observed in serum LDL-C, HDL-C, TC and TG levelsTable 3 – Genotypic and allelic allocation of MTHFR (C677T) an
Genotypes/alleles/
genetic model
CVD cases (n = 195) (%) 
MTHFR C677T
677CC 181 (92.82%) 
677 CT (CC vs CT) 14 (7.18%) 
677 TT (CC vs TT) 0 (0%) 
677 CT + TT (CC vs CT + TT) 14 (7.18%) 
677C 0.96 
677T (C vs T) 0.04 
MTR A2756G
2756AA 81 (41.54%) 
2756AG (AA vs AG) 110 (56.41%) 
2756GG (AA vs GG) 4 (2.05%) 
2756AG + GG (AA vs AG + GG) 114 (58.46%) 
2756A 0.7 
2756G (A vs G) 0.3 
OR and 95% CI were calculated with MTHFR 677CC and MTR 2756AA gen
y Some genotype combinations were not observed, so it was not possible
* Signiﬁcant values.among cases and controls. The mean total cholesterol of cases
and controls was 184.62  60.95 and 128.82  31.47, those of
triglycerides were 204.58  81.42 and 123.30  26.6 and those
of LDL-C were 129.78  71.37 and 77.20  19.30 respectively.
However, HDL-C level appeared to be in lower range in patients
(36.18  9.82) and higher in controls (51.39  6.75, p < 0.0001).
In comparison to DM (18.1%), history of HTN (53.33%) was
found to be higher in patients as a co-morbid condition. The
percentage of male patients with HTN as a co-morbid disease
was more than DM, whereas sex-speciﬁc comparison showed
that frequency of CVD and DM was almost similar in both male
(19.53%) and female (19.40%) patients.
Among different non-genetic risk factors, lifestyle param-
eters namely sedentary behavior, history of previous smokingd MTR (A2756G) polymorphism in study groups.
Controls (n = 240) (%) OR (95% CI)* p-Value
238 (99.17%) 1 (Reference)
2 (0.83%) 9.20 [2.06–41.01] 0.00047*
0 (0%) Not possibley –
2 (0.83%) 9.20 [2.06–41.01] 0.00047*
0.996 1 (Reference)
0.004 8.89 [2.01–39.40] 0.00053*
131 (54.58%) 1 (Reference)
109 (45.42%) 1.63 [1.11–2.39] 0.01*
0 (0%) Not possibley –
109 (45.42%) 1.69 [1.15–2.47] 0.007*
0.8 1 (Reference)
0.2 1.48 [1.09–2.00] 0.01*
otype as reference group.
 to calculate odds ratio.
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and low levels of HDL-C were highly signiﬁcant ( p < 0.0001) to
be associated with CVD.
3.2. Genetic factors
Genotypic and allelic allocation of both MTHFR (C677T) and
MTR (A2756G) gene polymorphisms among cases and controls
are summarized in Table 3. The MTHFR genotype distribution
was in the range of Hardy–Weinberg equilibrium for both
study participants (cases: x2 = 0.27, p = 0.05; controls: x2 = 0,
p = 0.05). The frequencies of CC vs CT and CC vs CT + TT
[OR = 9.20, 95% CI (2.06–41.01); p = 0.00047] genotypes differedTable 4 – Combined genotype frequencies of MTHFR and MTR 
Variant MTHFR
C677T/MTR A2756G
CVD cases (n = 195) (%) Con
677CC/2756AA 73 (37.44%) 
677CT/2756AA 8 (4.10%) 
677TT/2756AA 0 
677CC/2756AG 104 (53.33%) 
677CT/2756AG 6 (3.08%) 
677TT/2756AG 0 
677CC/2756GG 4 (2.05%) 
677CT/2756GG 0 
677TT/2756GG 0 
y Some genotype combinations were not observed, so it was not possibl
* Significant values.
Table 5 – MTHFR (C677 T) gene polymorphism in different ethn
Ethnicity Frequency of genotypes (%) Frequency
Cases Controls Cases 
CC CT TT CC CT TT C T 
North Indian 92.82 7.18 0 99.17 0.83 0 96.41 3.5
North Indian 70.9 24.6 4.4 73.59 25 1.4 83.3 16.7
East Indian 51.6 21.6 26.72 72.94 14.11 12.9 61.96 38.0
South Indian 73.3 26.7 0 80 20 0 86 14 
Arabs 64.2 32.1 3.7 72.2 25.8 2 80 20 
Turkish 48.7 40 11.3 55.9 40.7 3.4 69 31 
Italian 29.2 48.7 22.1 24.7 52.5 22.8 53.5 46.5
CAD, coronary artery disease; EH, essential hypertension; MI, myocardia
Table 6 – MTR (A2756G) gene polymorphism in different ethni
Ethnicity Frequency of genotypes (%) Frequen
Cases Controls Cases 
AA AG GG AA AG GG A G
North Indian 41.54 56.41 2.05 54.58 45.52 0 69.74 30.
South Indian 94 6 0 210 0 0 97 3 
South Indian 170 149 31 126 141 12 69.8 31.
Chinese 88.9 10.7 0.39 84.6 15 0.4 94.2 5.
Tunisian 72 26.2 1.9 80.5 18.7 0.9 85 15 
Italian 70 28 2 68.9 29 2.1 83.99 16.
CAD, coronary artery disease; EH, essential hypertension; MI, myocardiasigniﬁcantly between the two groups. OR for C vs T allele
showed that 'T' allele of MTHFR gene was adding 8.89 folds
( p = 0.00053) risk for the development of CVD in our population.
There was a statistical signiﬁcant difference between genotypic
distribution for MTR (A2756G) polymorphism between patients
(x2 = 22.1, p = 0.001) and controls (x2 = 20.72, p = 0.001). Logistic
regression for AA vs AG [OR = 1.63, 95% CI (1.11–2.39); p = 0.01]
and AA vs AG + GG [OR = 1.69, 95% CI (1.15–2.47); p = 0.007]
genotypes appeared to have a signiﬁcant association. The
mutant ‘‘G’’ allele of MTR (A2756G) polymorphism is having
a signiﬁcant role for the development of CVD phenotype in
the study population [OR = 1.48, 95% CI (1.09–2.00); p = 0.01]
(Table 4).gene polymorphisms in study groups.
trols (n = 240) (%) OR (95% CI)* p-Value
130 (54.16%) 1 (Reference)
1 (0.42%) 14.25 [1.75–116.17] 0.01*
0 Not possibley
108 (45%) 1.71 [1.16–2.54] 0.007*
1 (0.42%) 10.68 [1.26–90.48] 0.03*
0 Not possibley
0 Not possibley
0 Not possibley
0 Not possibley
e to calculate odds ratio.
ic groups.
 of alleles (%) Type of CVD
phenotype
Reference
Controls
C T
9 99.5 0.5 CAD, MI, Arrhythmia Present study
 86.1 13.9 CAD Pandey et al. (2011)47
3 63.97 36.12 CAD Dhar et al. (2010)43
90 10 MI and DM Angeline et al. (2009)66
85 15 CAD Abu-Amero et al. (2003)54
76 24 CAD Caner et al. (2008)60
 50.93 49.07 Arrhythmia Giusti et al. (2007)55
l infarction; DM, diabetes mellitus.
c groups.
cy of alleles (%) Type of CVD phenotype Reference
Controls
 A G
26 77 23 CAD, MI, Arrhythmia Present study
100 – CAD Kanth et al. (2011)29
2 70.4 29.6 CAD Lakshmi (2011)45
8 92.1 7.9 Cerebrovascular diseases Aifan et al. (2009)67
90 10 MI Jemaa et al. (2008)65
01 83.39 16.61 Arrhythmia Giusti et al. (2007)55
l infarction.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 4 2 1 – 4 3 0 4274. Discussion and conclusion
Study of both non-genetic and genetic determinants can give
an apparent delineation of disease pathophysiology and the
later generates possible options for disease management. The
classical non-genetic risk factors, which were undertaken in
the present study included dwelling, physical inactivity,
smoking, alcohol intake, diet pattern, any history of concomi-
tant disease including HTN, DM, etc. Main portion of the
patient participants of our study belonged to urban counter-
parts of Jammu region. Sedentary behavior was adopted by
higher percentage of patient population as their basic lifestyle
pattern. Smoking emerged to be potent risk factor for CVD in
our population. Men, when compared to women, were
reportedly more prone to smoking. Strong association of
smoking with CAD was also reported by Achari and Thakur
(2004).35 A signiﬁcant pattern of ﬂuctuations in biochemical
variables (LDL, HDL, TC and TG) from the normal range was
observed in cases. In comparison to DM, the present study
revealed that history of HTN in patients was a predominant co-
morbid state. Iqbal and researchers (2012) suggested HTN as
one of major contributors for CVD phenotype.36 On the
contrary, a previous report37 revealed a higher incidence of
HTN and DM as concomitant conditions than HTN and CAD, in
Jammu region of J&K state. Aggarwal et al. (2012) reported high
prevalence of smoking, dyslipidemia and HTN in Indian
patients with CAD.38 Study undertaken by Iyer et al. (2011)4
and De et al. (2004)39 are in concordance with the present
study.
Every individual has a unique identity in terms of both
phenotype and genotype. Of course, it is a universal truth that
99.9% of human genome architecture is identical with a
difference of only 0.1%.40 In the last couple of decades, a
tremendous effort has been made by researchers worldwide
to elucidate a functional link between such human genetic
variations particularly SNPs and complex traits including
CVDs. Since, MTHFR and MTR genes are the key genes of
homocysteine pathway, any variation in these genes could
bring a deviation in the said pathway from routine function-
ing and is correlated to the appearance of complex cardio-
vascular phenotypes. The present study has been designed
to elucidate the association of MTHFR (C677T) and MTR
(A2756G) gene variants in susceptibility of CVDs in populace
of Jammu region.
In our study, we found higher frequency of T allele in cases
as compared to controls, and a signiﬁcant association of the
said polymorphism was observed in CVD patients. Similarly,
Dhar et al. (2010) found T allele to be signiﬁcantly related with
CAD in eastern Indian population.41 Matam et al. (2014)
depicted that T allele greatly inﬂuences the risk of CAD in
south Indian population (T vs C: OR = 3.1; p = 0.00001).42
Research on other Indian populations has shown MTHFR
(C677T) gene polymorphism to be a strong candidate for
CVDs.16,43,44 A non-signiﬁcant association with CAD was
formulated by Pandey et al. (2011) despite having higher
frequency of T allele in cases than the controls.45 Vasisht and
colleagues (2002) also found higher frequency trend for 'T'
allele in north Indian CAD patients than in controls but these
associates failed to proclaim any signiﬁcant association of thesaid polymorphism with the atherosclerotic coronary pheno-
type.46 Study conducted by other researchers showed negative
association of MTHFR gene polymorphism with CAD.29,47
Regarding different worldwide population groups strong
positive relationship between TT genotype of MTHFR
(C677T) SNP and risk of CVD has been described by some
eminent researchers,48–50 whereas a couple of case–control
studies presented contradictory results.51–54 Recently, it has
been proposed that evaluation of CVD risk in T2DM patients
cannot be carried out on the presence of either MTHFR C677T
polymorphism or mutant genotypes.55 Investigations on
MTHFR gene polymorphisms by various distinguished
researchers worldwide reported MTHFR (C677T) gene variant
as a feeble marker for CAD,29,52,56–58 arrhythmia,53 MI50 and
stroke.59 Conversely, Kluijtmans and associates (1996)
reported positive association of homozygous TT genotype
with a three-fold increase in risk for premature CVD.19 Several
research studies have assessed an apparent association of
MTHFR (677-TT) genotype with hyper-homocystinuria and
CVD.60–62 A comparison on genotypic and allelic frequency
of MTHFR gene polymorphism in relation to CVD phenotypes
between present study and other studies is depicted in
Table 5.
Regarding MTR gene, the present study has ﬁgured out
higher frequency of G allele in cases than in controls. Similarly,
Jemaa et al. (2008) revealed signiﬁcant and dependent
association between the G allele of the MTR gene and MI in
Tunisian population.63 Huang and colleagues (2008), observed
a striking difference between MTHFR (C677T), MTR (A2756G)
gene polymorphisms and hyperlipidemia in Northern Chinese
subjects.64 These investigators reported that the subjects with
G allele of MTR gene and increased levels of homocysteine had
higher risk of combined hyperlipidemia. On the contrary,
insigniﬁcant association was observed by Lakshmi et al.
(2011)43 and Kanth et al. (2011).29 Singh and Lele (2012), in
their meta-analysis declared MTR (A2756G) gene (OR = 1.61;
p = 0.06) as a weak marker for CAD.7 Salomon and co-authors
(2001) suggested that homozygosity for MTR 2756G genotype
did not confer risk for idiopathic venous thromboembolism.65
As in the results concerning MTHFR gene, controversial results
were also shown by MTR (A2756G) gene polymorphism and
risk of CVD among different populations (Table 6).
In the work under report, we observed a signiﬁcant
association of both MTHFR (C677T) and MTR (A2756G) gene
polymorphisms with CVD. The possible limitations of the
present study may include small sample size, sample
enrolment from single region of J&K state and lack of
homocysteine measurements. Plasma homocysteine levels
appear to increase with age and sex as are CVDs. In the present
study the mean age of the patients also differs signiﬁcantly
from the controls, which speculates the attribution of risk of
CVD to difference in plasma homocysteine levels in the study
participants. Since, we were not able to measure homocyste-
ine levels in the study participants hence; it is difﬁcult to reach
a deﬁnite conclusion. The study needs to be further replicated
by taking into consideration the above-mentioned limitations,
which may help in ascertaining the results. We intend to plan
a wider research study on diversity of gene variations of
homocysteine metabolism in CVD among populations of three
regions of the J&K state in future.
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